Comprehensive guides with safety triggers, contrarian views, research gaps, and practical protocol references.
A clear-eyed map of the peptides and nutritional adjuncts being used for attention and executive function — what the literature supports, what the FDA has banned, and where the biohacking consensus is running ahead of the data.
An evidence-based exploration of focus and ADHD peptides including Semax, Selank, Noopept, Cerebrolysin and their nutritional adjuncts — with the regulatory, retraction and translational-gap landscape that the biohacking coverage tends to leave out.
From Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record — five realities of the peptide cognition frontier, and the regulatory minefield around them.
An evidence-based exploration of memory-management peptides including Dihexa, Semax, Selank, P21, and Cerebrolysin. We examine synaptogenic potency claims alongside oncogenic risk, the FDA's 2024 compounding ban, and where clinical evidence ends and biohacking speculation begins.
The peptide revolution promises to rewire your brain — but your immune system might have other plans.
An evidence-based exploration of neuroprotective peptides including GLP-1 receptor agonists, Selank, and Dihexa. We examine clinical promise alongside immunogenicity risks, grey-market purity concerns, and the thin line between neuroregeneration and oncogenic overstimulation.
The gland behind your breastbone has been shrinking since puberty — and taking your immune system with it.
Thymic involution is the progressive shrinkage of the thymus gland that accelerates immune aging. Thymic peptides like Thymosin β4 and Thymalin offer a regenerative approach to reversing this decline, with applications spanning cardiac repair, immune reconstitution, and even hair regrowth.
We are no longer blocking baldness -- we are rebooting the follicle from the inside out.
Emerging research reveals that hair loss is not simply a hormonal problem but a multi-layered signaling and metabolic failure. By targeting the CXXC5 molecular blockade, shifting stem-cell metabolism with MPC inhibitors, and rebuilding the follicle micro-environment with regenerative peptides, science is rewriting the rules of follicle restoration.
Our DNA is not a static blueprint of decline but a dynamic epigenetic landscape that can be re-tuned through precise molecular signaling.
Aging is a profound loss of transcriptional access, not just mechanical wear. Mitochondrial peptides like MOTS-c and SS-31, alongside epigenetic bioregulators such as Epitalon and Livagen, are rewriting the longevity playbook by restoring chromatin architecture and stabilizing the mitochondrial membrane. This protocol maps the frontier from deheterochromatinization to FDA-approved cristae repair.
Your body still has the blueprint for repair — peptides and pressurized oxygen are the missing construction crew.
Peptide therapy and hyperbaric oxygen work as architect and builder to unlock genomic repair mechanisms your body already possesses. From GHK-Cu's ability to reset 31.2% of human genes to MOTS-c's mitochondrial master switch, these tools move recovery science from symptom management to biological system optimization.
Your skin loses 1% of its collagen every year after 20—but peptide signaling can tell your fibroblasts to rebuild what time has taken.
A deep dive into the peptide protocols that restore skin elasticity from the cellular level up. From copper peptides that reactivate collagen genes to telomere-protective compounds that extend the lifespan of dermal cells, this is the science of reversing structural skin aging.
Mitochondria-derived peptides like SS-31 and MOTS-c are rewriting the rules of cellular energy — but the translational gap between mouse models and human performance remains wide open.
The mitochondrial revolution is moving beyond generic antioxidants toward precision peptides that stabilize the inner membrane and restore fading cellular signals. SS-31 tightens the elastic of the cell while MOTS-c acts as an exercise mimetic encoded in our own DNA — yet clinical reality checks remind us that promising preclinical data does not always survive the journey to the pharmacy.
DSIP was named for inducing delta sleep, but independent labs failed to replicate that in humans, no one has found its receptor or gene, and its best human stress trial found zero effect. Fascinating biology, unproven clinically.
DSIP (Delta Sleep-Inducing Peptide / Emideltide) is a nonapeptide studied for sleep, stress, and opioid withdrawal. Its human sleep data is inconsistent, its receptor is unknown, rodent stress effects failed to translate to humans, and it is not FDA-approved, with a PCAC review set for July 2026.
Cerebrolysin is a porcine-brain peptide mixture sold as a master key for brain repair. It has decades of human trials, approval in 50+ countries, no FDA approval, and a Cochrane safety signal that complicates the story.
Cerebrolysin is a porcine-derived neurotrophic peptide preparation studied for stroke, TBI, and dementia. Human RCT data exists but is heterogeneous and industry-weighted, independent Cochrane reviews find no mortality benefit and a serious-adverse-event signal, and it is not FDA-approved.
KPV is the three-amino-acid tail of alpha-MSH: it keeps the parent hormone's anti-inflammatory power, drops the pigmentation, and targets inflamed tissue through the PepT1 transporter. The catch: every result so far is from cells or animals.
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory, antimicrobial, gut, and skin applications. Evidence is entirely preclinical, with no completed human trials, and the compound is under FDA PCAC review for July 2026.
A 16-amino-acid fragment of human growth hormone engineered to trigger fat metabolism without activating the GH receptor, AOD-9604 cleared early clinical trials for obesity before its pivotal Phase IIb collapsed under a placebo response. Now stripped of FDA Category 2 status and banned by WADA, its most interesting data may be in a direction nobody expected: cartilage repair.
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone, with an added N-terminal tyrosine. It selectively activates beta-3 adrenergic receptors to stimulate lipolysis without engaging the GH receptor, producing no measurable effect on IGF-1 or glucose. Its Phase IIb obesity trial (OPTIONS, 536 participants) was terminated in 2007 when placebo outperformed expectations. Preclinical cartilage regeneration data has since repositioned the compound toward joint repair, but no human joint trial exists.
The oral compound that reliably raises GH and IGF-1 to youthful levels, delivers measurable gains in lean mass and sleep architecture, yet consistently failed to translate those biomarker wins into functional outcomes across 30 years of clinical trials.
MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that selectively agonises the ghrelin receptor (GHS-R1a). It increases 24-hour GH secretion by up to 97% and IGF-1 by 60-79%, producing verified gains in fat-free mass and sleep quality. However, the lean mass does not translate to strength, the bone turnover does not translate to density, and insulin resistance is a consistent pharmacological cost.
The first FDA-approved peptide that targets the brain's desire circuitry instead of the body's vascular hardware, opening a new front in sexual medicine, appetite regulation, and central neuromodulation.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and centrally acting melanocortin receptor agonist FDA-approved for premenopausal female HSDD. It bypasses peripheral blood flow entirely, activating MC3R and MC4R in the hypothalamus to trigger dopamine and oxytocin release. Emerging data positions it as a post-GLP-1 weight rebound shield and a rescue therapy for PDE5 inhibitor non-responders in men.
The first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.
Tirzepatide is an imbalanced dual GIP/GLP-1 receptor agonist achieving 15-22.5% body weight reduction, HbA1c cuts of up to 2.6%, FDA approval for sleep apnoea, and a 38% reduction in heart failure events. Its biased agonism at the GLP-1 receptor avoids receptor desensitisation, but rapid weight loss raises real concerns about bone density and lean mass.
The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.
Semaglutide is a modified GLP-1 analogue with a ~1-week half-life, proven to reduce body weight by 10-17%, cut cardiovascular events by 20%, resolve fatty liver disease, and slow kidney decline. Its reach now extends into addiction, sleep apnea, and neuroinflammation.
An 11-amino-acid peptide derived from erythropoietin's helix-B surface that selectively activates the Innate Repair Receptor, triggering nerve regeneration and tissue protection without the blood-thickening risks of EPO.
ARA-290 isolates the tissue-repair signal from erythropoietin without stimulating red blood cell production. Phase II trials showed a 23% increase in corneal nerve fiber area in sarcoidosis patients, proving structural nerve regeneration rather than symptomatic relief. The molecule also improved HbA1c and lipid profiles in diabetic trials, with effects lasting weeks beyond the final dose.